Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-MVST Cells for Refractory Viral Infections in Immunocompromised Children and Young Adults
NCT06926894Phase 1Recruiting
- Start
- Apr 2025
- Primary completion
- Apr 2029
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of virus-specific T cells in Epstein-Barr virus infection, cytomegalovirus infection (CMV), adenovirus infection and 1 more (3 arms). Primary endpoints: Incidence of toxicity that leads to safety endpoint up to 28 days and Incidence of graft-versus-host disease (GVHD) post-infusion up to 28 days. Started Apr 2025; status: recruiting.
02
Drugs
virus-specific T cells
03
Conditions
Epstein-Barr virus infectioncytomegalovirus infection (CMV)adenovirus infectionBK virus infection
Beyond the preview
Go deeper on NCT06926894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06926894.